Home > Insider Trading > Filing (0001179110-20-010780)

Filing Details

Accession Number:: 0001179110-20-010780
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-11-03 19:52:52
Reporting Period:: 2020-11-02

Accepted Time:: 2020-11-03 19:52:52
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070081	Ptc Therapeutics Inc.	PTCT	Pharmaceutical Preparations (2834)	043416587

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1578962	Walter Stuart Peltz	C/O Ptc Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-11-02	50,000	$10.85	106,085	No	4	M	Direct
Common Stock	Disposition	2020-11-02	29,073	$53.13	77,012	No	4	S	Direct
Common Stock	Disposition	2020-11-02	9,114	$53.86	67,898	No	4	S	Direct
Common Stock	Disposition	2020-11-02	11,813	$54.79	56,085	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-11-02	50,000	$10.85	50,000	$10.85

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,115		2023-05-15	No	4	M	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right To Buy)	$490.80	2021-04-27	541	541	Direct
Common Stock	Stock Option (Right To Buy)	$218.40	2022-01-10	416	416	Direct
Common Stock	Stock Option (Right to Buy)	$10.85	2023-05-15	10,694	10,694	Direct
Common Stock	Stock Option (Right To Buy)	$27.05	2024-01-27	200,000	200,000	Direct
Common Stock	Stock Option (Right To Buy)	$51.00	2025-01-01	300,000	300,000	Direct
Common Stock	Stock Option (Right To Buy)	$30.86	2026-01-03	175,000	175,000	Direct
Common Stock	Stock Option (Right To Buy)	$11.23	2027-01-02	26,000	26,000	Direct
Common Stock	Stock Option (Right To Buy)	$18.01	2028-01-02	200,000	200,000	Direct
Common Stock	Stock Option (Right To Buy)	$33.02	2029-01-21	265,000	265,000	Direct
Common Stock	Stock Option (Right To Buy)	$33.02	2029-01-21	55,000	55,000	Direct
Common Stock	Stock Option (Right To Buy)	$51.16	2030-01-28	192,500	192,500	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2021-04-27	541	541	Direct
2022-01-10	416	416	Direct
2023-05-15	10,694	10,694	Direct
2024-01-27	200,000	200,000	Direct
2025-01-01	300,000	300,000	Direct
2026-01-03	175,000	175,000	Direct
2027-01-02	26,000	26,000	Direct
2028-01-02	200,000	200,000	Direct
2029-01-21	265,000	265,000	Direct
2029-01-21	55,000	55,000	Direct
2030-01-28	192,500	192,500	Direct

Footnotes

This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.42 to $53.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.42 to $54.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.42 to $55.06 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Currently exercisable.
This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
This option was granted on January 29, 2020 and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 29, 2021.